<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop(Peter MacCallum Cancer Centre), Gillian Mitchell(Peter MacCallum Cancer Centre), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Michael Friedländer(Prince of Wales Hospital), Alexander Dobrovic(The University of Melbourne), Anna DeFazio(Peter MacCallum Cancer Centre), David D.L. Bowtell(The University of Melbourne), Cliff Meldrum(John Hunter Hospital), Joshy George(Jackson Laboratory), Sián Fereday(Peter MacCallum Cancer Centre), Stephen B. Fox(Peter MacCallum Cancer Centre), Michael J. Birrer(University of Arkansas Medical Center), Catherine Emmanuel(Peter MacCallum Cancer Centre), Colin J.R. Stewart(King Edward Memorial Hospital)
Cited by 1,173
Related Papers
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
The 2019 World Health Organization classification of tumours of the breast
|Histopathology|2020|1.1k